Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient

被引：6

作者：

Liverman, Rochelle ^{[1
]}

Chandran, Mary Moss ^{[2
]}

Crowther, Barrett ^{[3
]}

机构：

[1] Childrens Healthcare Atlanta, Dept Pharm, Atlanta, GA USA

[2] Childerens Hosp Colorado, Dept Pharm, Aurora, CO USA

[3] Univ Colorado Hosp, Ambulatory Care Pharm Serv, Aurora, CO USA

来源：

PHARMACOTHERAPY | 2021年 / 41卷 / 01期

关键词：

clinical pharmacology; graft rejection; immunosuppressive agents; kidney transplantation; pediatrics; transplant recipients; ANTIBODY-MEDIATED REJECTION; SOLID-ORGAN TRANSPLANTATION; RABBIT ANTITHYMOCYTE GLOBULIN; LOW-DOSE CYCLOSPORINE; LATE STEROID WITHDRAWAL; MYCOPHENOLATE-MOFETIL; RANDOMIZED-TRIAL; RENAL-TRANSPLANTATION; CALCINEURIN INHIBITOR; TACROLIMUS MONOTHERAPY;

D O I：

10.1002/phar.2483

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pediatric kidney transplantation has experienced considerable growth and improvement in patient and allograft outcomes over the past 20 years, in part due to advancements in immunosuppressive regimens and management. Despite this progress, care for this unique population can be challenging due to limited pediatric transplant data and trials, intricacies related to differences in children and adolescents compared with their adult counterparts, and limitations to long-term survival facing all solid organ transplant populations. Immunosuppression and infection prevention practices vary from one pediatric transplant center to another and clinical controversies exist surrounding treatment and dosing. This review aims to summarize key aspects of pharmacologic management in this population and present pertinent data that describe the influence of practice to serve as a resource for practitioners caring for this unique specialty patient population. Additionally, this review highlights select controversies that exist within pediatric kidney transplantation.

引用

页码：77 / 102

页数：26

共 200 条

[1]

AbbVie Inc. USA, 2018, GENGRAF PRESCRIBING

[2] Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome [J].

Admiraal, Rick ;

Jol-van der Zijde, Cornelia M. ;

Furtado Silva, Juliana M. ;

Knibbe, Catherijne A. J. ;

Lankester, Arjan C. ;

Boelens, Jaap Jan ;

Hale, Goeff ;

Etuk, Aniekan ;

Wilson, Melanie ;

Adams, Stuart ;

Veys, Paul ;

van Kesteren, Charlotte ;

Bredius, Robbert G. M. .

CLINICAL PHARMACOKINETICS, 2019, 58 (12) :1609-1620

[3]

Advisory Committee on Immunization Practices (ACIP), 2020, RECOMMENDED IMMUNIZA

[4] Azathioprine Versus Mycophenolate Mofetil in Combination with Tacrolimus and Steroids Maintenance in Pediatric Kidney Transplantation [J].

Al-Mowaina, Sahar .

TRANSPLANTATION, 2018, 102 :S839-S839

[5] Efficacy and safety of three times daily dosing of tacrolimus in pediatric kidney transplantation patients: A single-center comparative study [J].

Alabdulkarim, Zinah ;

Al-jedai, Ahmed ;

Alkortas, Delal ;

Alhasan, Khalid ;

Devol, Edward .

PEDIATRIC TRANSPLANTATION, 2020, 24 (06)

[6] The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review [J].

AlDabbagh, M. A. ;

Gitman, M. R. ;

Kumar, D. ;

Humar, A. ;

Rotstein, C. ;

Husain, S. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (03) :770-781

[7]

Alexion Pharmaceuticals Inc, 2018, ULTOMIRIS PRESCRIBIN

[8]

Allen UD, 2005, ADV EXP MED BIOL, V568, P25

[9] Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice [J].

Allen, Upton D. ;

Preiksaitis, Jutta K. .

CLINICAL TRANSPLANTATION, 2019, 33 (09)

[10]

[Anonymous], 2009, Am J Transpl, V9, pS1, DOI DOI 10.1111/J.1600-6143.2009.02834.X

← 1 2 3 4 5 6 7 8 9 10 →